ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Acidosis,Mixed acid-base disorders,Acid-base disorders,Metab,N
1,2,Disseminated intravascular coagulation,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
2,1,Arteriosclerosis coronary artery,Coronary artery disorders NEC,Coronary artery disorders,Card,N
2,2,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
2,3,Coma,Coma states,Neurological disorders NEC,Nerv,N
2,4,Myocardial ischaemia,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
3,1,Blood pressure decreased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
3,2,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3,3,Coma,Coma states,Neurological disorders NEC,Nerv,N
4,1,Cardiac ventricular thrombosis,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
4,2,Haemodynamic instability,Non-site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
4,3,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4,4,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
5,1,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,Y
6,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
7,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,Y
7,2,Underdose,Underdoses NEC,Overdoses and underdoses NEC,Inj&P,N
8,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
8,2,Underdose,Underdoses NEC,Overdoses and underdoses NEC,Inj&P,N
9,1,Arterial thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
9,2,Blood lactic acid increased,Blood gas and acid base analyses,"Metabolic, nutritional and blood gas investigations",Inv,N
9,3,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
9,4,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
9,5,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
9,6,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
9,7,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
9,8,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
9,9,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
9,10,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
10,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
11,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
11,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
11,3,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
12,1,Aphasia,Cortical dysfunction NEC,Neurological disorders NEC,Nerv,N
12,2,Cerebral infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
12,3,Facial paralysis,Facial cranial nerve disorders,Cranial nerve disorders (excl neoplasms),Nerv,N
12,4,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
12,5,Ischaemic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
12,6,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
13,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
13,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,Y
14,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
15,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
15,2,Body temperature increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
15,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
15,4,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
15,5,Heart rate increased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
15,6,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
15,7,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
15,8,Oxygen saturation decreased,Blood gas and acid base analyses,"Metabolic, nutritional and blood gas investigations",Inv,N
15,9,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
16,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
16,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,Y
17,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
17,2,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
18,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
18,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
18,3,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
18,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
18,5,Respiratory distress,Breathing abnormalities,Respiratory disorders NEC,Resp,N
18,6,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
19,1,Catheter site related reaction,Implant and catheter site reactions,Administration site reactions,Genrl,N
19,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
19,3,Extravasation,General signs and symptoms NEC,General system disorders NEC,Genrl,N
19,4,Inflammation,Inflammations,General system disorders NEC,Genrl,N
19,5,Injection site discomfort,Injection site reactions,Administration site reactions,Genrl,N
19,6,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
19,7,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
20,1,Body temperature decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
20,2,Unresponsive to stimuli,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
21,1,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
21,2,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
21,3,Coma,Coma states,Neurological disorders NEC,Nerv,N
21,4,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
21,5,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
21,6,Hypoxia,Conditions associated with abnormal gas exchange,Respiratory disorders NEC,Resp,N
21,7,Respiratory distress,Breathing abnormalities,Respiratory disorders NEC,Resp,N
21,8,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
21,9,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
21,10,Underdose,Underdoses NEC,Overdoses and underdoses NEC,Inj&P,N
22,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
23,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
23,2,Coagulopathy,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
24,1,Coagulopathy,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
24,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
24,3,Necrotising fasciitis,Muscle and soft tissue infections,Infections - pathogen unspecified,Infec,Y
24,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
25,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
25,2,Coagulopathy,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
26,1,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
27,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
28,1,Ischaemic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
29,1,Ischaemic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
30,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
31,1,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
32,1,Ischaemic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
33,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
34,1,Ischaemic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
35,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
36,1,Ischaemic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
37,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
38,1,Cardiac ventricular thrombosis,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
39,1,Ischaemic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
40,1,Ischaemic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
41,1,Drug ineffective for unapproved indication,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
41,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
42,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
42,2,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
43,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
43,2,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
43,3,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
44,1,Circumstance or information capable of leading to medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
44,2,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
44,3,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
45,1,Cardiac ventricular thrombosis,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
46,1,Cardiac ventricular thrombosis,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,Y
46,2,Coronary artery embolism,Coronary artery disorders NEC,Coronary artery disorders,Card,N
46,3,Embolic cerebellar infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
46,4,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
47,1,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
47,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
